Accéder au contenu
Merck
Toutes les photos(1)

Documents

Y0000808

Sodium phenylbutyrate

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

4-PBA, 4-Phenylbutyric acid, 4-phenylbutyrate, Buphenyl, Sodium 4-phenylbutyrate, TriButyrate

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C10H11NaO2
Numéro CAS:
1716-12-7
Poids moléculaire :
186.18
Numéro MDL:
MFCD00800247
Code UNSPSC :
41116107
ID de substance PubChem :
329831161
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

sodium phenylbutyrate

Fabricant/nom de marque

EDQM

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

2-8°C

Chaîne SMILES 

[Na+].[O-]C(=O)CCCc1ccccc1

InChI

1S/C10H12O2.Na/c11-10(12)8-4-7-9-5-2-1-3-6-9;/h1-3,5-6H,4,7-8H2,(H,11,12);/q;+1/p-1

Clé InChI

VPZRWNZGLKXFOE-UHFFFAOYSA-M

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Catégories apparentées

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Sodium phenylbutyrate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Actions biochimiques/physiologiques

Sodium phenylbutyrate is a histone deacetylase inhibitor.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

Y0000809

Sodium phenylbutyrate impurity C, European Pharmacopoeia (EP) Reference Standard

1614512

Sodium phenylbutyrate, United States Pharmacopeia (USP) Reference Standard

1614556

Phenylbutyrate Related Compound B, United States Pharmacopeia (USP) Reference Standard

1614523

Phenylbutyrate Related Compound A, United States Pharmacopeia (USP) Reference Standard

1614534

Phenylbutyrate Related Compound C, United States Pharmacopeia (USP) Reference Standard

PHR3080

Phenylbutyrate Related Compound A, pharmaceutical secondary standard, certified reference material

PHR3081

Phenylbutyrate Related Compound B, pharmaceutical secondary standard, certified reference material

PHR3082

Phenylbutyrate Related Compound C, pharmaceutical secondary standard, certified reference material

PHR3237

Sodium Phenylbutyrate, pharmaceutical secondary standard, certified reference material

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Choose from one of the most recent versions:

Certificats d'analyse (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Elisabeth Kemter et al.
The Journal of biological chemistry, 289(15), 10715-10726 (2014-02-26)
Uromodulin (UMOD)-associated kidney disease (UAKD) belongs to the hereditary progressive ER storage diseases caused by maturation defects of mutant UMOD protein. Current treatments of UAKD patients are symptomatic and cannot prevent disease progression. Two in vitro studies reported a positive
Sotaro Naoi et al.
The Journal of pediatrics, 164(5), 1219-1227 (2014-02-18)
To examine the effects of 4-phenylbutyrate (4PB) therapy in a patient with progressive familial intrahepatic cholestasis type 2. A homozygous c.3692G>A (p.R1231Q) mutation was identified in ABCB11. In vitro studies showed that this mutation decreased the cell-surface expression of bile
Viola Pomozi et al.
The Journal of investigative dermatology, 134(4), 946-953 (2013-12-20)
Mutations in the ABCC6 gene cause soft-tissue calcification in pseudoxanthoma elasticum (PXE) and, in some patients, generalized arterial calcification of infancy (GACI). PXE is characterized by late onset and progressive mineralization of elastic fibers in dermal, ocular, and cardiovascular tissues.
Norihiko Yokoi et al.
Nature medicine, 21(1), 19-26 (2014-12-09)
Epilepsy is one of the most common and intractable brain disorders. Mutations in the human gene LGI1, encoding a neuronal secreted protein, cause autosomal dominant lateral temporal lobe epilepsy (ADLTE). However, the pathogenic mechanisms of LGI1 mutations remain unclear. We
Masayuki Koyama et al.
American journal of physiology. Heart and circulatory physiology, 306(9), H1314-H1323 (2014-03-13)
Pulmonary arterial hypertension (PAH) is characterized by vasoconstriction and vascular remodeling of the pulmonary artery (PA). Recently, endoplasmic reticulum (ER) stress and inappropriate adaptation through the unfolded protein response (UPR) have been disclosed in various types of diseases. Here we
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique